FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589773896> ?p ?o ?g. }

• W2589773896 endingPage "415" @default.
• W2589773896 startingPage "415" @default.
• W2589773896 abstract "415 Background: The Retrospective analysis of Sorafenib (So) as the first- or second- target therapy (RESET) study in metastatic renal cell carcinoma (mRCC) patients assessed the use and safety of sorafenib under daily-life treatment conditions in a community-based patient population in Italian centers. Methods: RESET was a retrospective, observational, non-interventional field study in mRCC patients. Treatment decisions were determined by each physician according to local prescribing guidelines and clinical practice. Patients for whom a decision to treat with sorafenib single agent as first- or second- target therapy (TT) for mRCC has been made, were eligible for inclusion. Patients that started So treatment between January 1, 2008 and December 31, 2010 were included. Data collection started retrospectively in 2012, in order to have a period of observation of at least 1 year up to 31st Dec 2011. Endpoints included safety, overall survival (OS), progression-free survival (PFS), response rate (RR), and treatment duration. Subgroup analyses included age, Eastern Cooperative Oncology Group performance status, prior therapy, number of metastases, and line of TT with So. Results: From February to Jululy 2012, 358 pts from 37 Italian centers were enrolled. The most common ≥ grade 3 drug-related adverse events were hand-foot skin reaction (6.3%), rash (2.3%), hypertension, fatigue, and diarrhea (1.7% each). In the overall population, median OS was 17.2 months (mos) (95% CI 15.5 – 19.6 mos) and median PFS was 5.9 mos (95% CI 5.0-6.8 mos). Median duration of treatment with So was 5.09 mos. Complete response was observed in 3 (0.8%) pts, partial response in 53(15.0%) pts and stable disease in 139(39.4%) pts. In pts receiving So as first- or second- TT, median OS was 19.9 mos (95% CI 15.4-25.3 mos) and 16.6 mos (95% CI 13.1-18.4 mos) respectively, and median PFS was 6.6 mos (95% CI 4.9-9.3 mos) and 5.3 mos (95% CI 4.4-6.2 mos) respectively. Conclusions: The efficacy and safety of So under routine clinical practice conditions in the setting of community-based practice in Italy were similar to that reported in prospective clinical trials. The efficacy of So was observed in the subgroup of pts receiving So as either the first or second TT for mRCC." @default.
• W2589773896 created "2017-03-03" @default.
• W2589773896 creator A5007854370 @default.
• W2589773896 creator A5018910230 @default.
• W2589773896 creator A5019053015 @default.
• W2589773896 creator A5022699386 @default.
• W2589773896 creator A5024574553 @default.
• W2589773896 creator A5034356923 @default.
• W2589773896 creator A5035120623 @default.
• W2589773896 creator A5040427285 @default.
• W2589773896 creator A5042436465 @default.
• W2589773896 creator A5050466636 @default.
• W2589773896 creator A5054491406 @default.
• W2589773896 creator A5055436796 @default.
• W2589773896 creator A5057926104 @default.
• W2589773896 creator A5071060598 @default.
• W2589773896 creator A5073892178 @default.
• W2589773896 creator A5074987624 @default.
• W2589773896 creator A5086312742 @default.
• W2589773896 creator A5087448164 @default.
• W2589773896 creator A5089708987 @default.
• W2589773896 creator A5090942847 @default.
• W2589773896 date "2013-02-20" @default.
• W2589773896 modified "2023-09-24" @default.
• W2589773896 title "Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience." @default.
• W2589773896 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.415" @default.
• W2589773896 hasPublicationYear "2013" @default.
• W2589773896 type Work @default.
• W2589773896 sameAs 2589773896 @default.
• W2589773896 citedByCount "0" @default.
• W2589773896 crossrefType "journal-article" @default.
• W2589773896 hasAuthorship W2589773896A5007854370 @default.
• W2589773896 hasAuthorship W2589773896A5018910230 @default.
• W2589773896 hasAuthorship W2589773896A5019053015 @default.
• W2589773896 hasAuthorship W2589773896A5022699386 @default.
• W2589773896 hasAuthorship W2589773896A5024574553 @default.
• W2589773896 hasAuthorship W2589773896A5034356923 @default.
• W2589773896 hasAuthorship W2589773896A5035120623 @default.
• W2589773896 hasAuthorship W2589773896A5040427285 @default.
• W2589773896 hasAuthorship W2589773896A5042436465 @default.
• W2589773896 hasAuthorship W2589773896A5050466636 @default.
• W2589773896 hasAuthorship W2589773896A5054491406 @default.
• W2589773896 hasAuthorship W2589773896A5055436796 @default.
• W2589773896 hasAuthorship W2589773896A5057926104 @default.
• W2589773896 hasAuthorship W2589773896A5071060598 @default.
• W2589773896 hasAuthorship W2589773896A5073892178 @default.
• W2589773896 hasAuthorship W2589773896A5074987624 @default.
• W2589773896 hasAuthorship W2589773896A5086312742 @default.
• W2589773896 hasAuthorship W2589773896A5087448164 @default.
• W2589773896 hasAuthorship W2589773896A5089708987 @default.
• W2589773896 hasAuthorship W2589773896A5090942847 @default.
• W2589773896 hasConcept C121608353 @default.
• W2589773896 hasConcept C126322002 @default.
• W2589773896 hasConcept C141071460 @default.
• W2589773896 hasConcept C167135981 @default.
• W2589773896 hasConcept C197934379 @default.
• W2589773896 hasConcept C2777472916 @default.
• W2589773896 hasConcept C2778019345 @default.
• W2589773896 hasConcept C2778570526 @default.
• W2589773896 hasConcept C2778695046 @default.
• W2589773896 hasConcept C2781230642 @default.
• W2589773896 hasConcept C2908647359 @default.
• W2589773896 hasConcept C71924100 @default.
• W2589773896 hasConcept C99454951 @default.
• W2589773896 hasConceptScore W2589773896C121608353 @default.
• W2589773896 hasConceptScore W2589773896C126322002 @default.
• W2589773896 hasConceptScore W2589773896C141071460 @default.
• W2589773896 hasConceptScore W2589773896C167135981 @default.
• W2589773896 hasConceptScore W2589773896C197934379 @default.
• W2589773896 hasConceptScore W2589773896C2777472916 @default.
• W2589773896 hasConceptScore W2589773896C2778019345 @default.
• W2589773896 hasConceptScore W2589773896C2778570526 @default.
• W2589773896 hasConceptScore W2589773896C2778695046 @default.
• W2589773896 hasConceptScore W2589773896C2781230642 @default.
• W2589773896 hasConceptScore W2589773896C2908647359 @default.
• W2589773896 hasConceptScore W2589773896C71924100 @default.
• W2589773896 hasConceptScore W2589773896C99454951 @default.
• W2589773896 hasIssue "6_suppl" @default.
• W2589773896 hasLocation W25897738961 @default.
• W2589773896 hasOpenAccess W2589773896 @default.
• W2589773896 hasPrimaryLocation W25897738961 @default.
• W2589773896 hasRelatedWork W2057452027 @default.
• W2589773896 hasRelatedWork W2100792025 @default.
• W2589773896 hasRelatedWork W2353570280 @default.
• W2589773896 hasRelatedWork W2366229560 @default.
• W2589773896 hasRelatedWork W2387003639 @default.
• W2589773896 hasRelatedWork W2392668288 @default.
• W2589773896 hasRelatedWork W2397189360 @default.
• W2589773896 hasRelatedWork W2589757954 @default.
• W2589773896 hasRelatedWork W2951987258 @default.
• W2589773896 hasRelatedWork W4292195411 @default.
• W2589773896 hasVolume "31" @default.
• W2589773896 isParatext "false" @default.
• W2589773896 isRetracted "false" @default.
• W2589773896 magId "2589773896" @default.
• W2589773896 workType "article" @default.